Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1
- Interventions
- Drug: placebo
- First Posted Date
- 2014-03-28
- Last Posted Date
- 2017-02-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 835
- Registration Number
- NCT02098395
- Locations
- 🇸🇪
Novo Nordisk Investigational Site, Örebro, Sweden
A Trial Investigating the Mechanism of Action of NNC0109-0012 (Anti-IL-20 mAb) Through Synovial Biopsies in Subjects With Rheumatoid Arthritis and an Inadequate Response to Methotrexate
Phase 2
Withdrawn
- Conditions
- InflammationRheumatoid Arthritis
- Interventions
- First Posted Date
- 2014-03-27
- Last Posted Date
- 2014-08-15
- Lead Sponsor
- Novo Nordisk A/S
- Registration Number
- NCT02097264
Evaluation of Optimal Dosing Conditions for GLP-1 Analogue NNC0113-0987 When Administered Orally in Healthy Male Subjects
Phase 1
Completed
- Conditions
- DiabetesHealthy
- Interventions
- Drug: NNC0113-0987
- First Posted Date
- 2014-03-24
- Last Posted Date
- 2015-01-29
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 122
- Registration Number
- NCT02094521
A Trial Comparing the Pharmacokinetic Properties of Faster-acting Insulin Aspart (FIAsp) After Different Injection Regions and Routes of Administration in Healthy Subjects
- First Posted Date
- 2014-03-17
- Last Posted Date
- 2017-02-17
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 21
- Registration Number
- NCT02089451
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany
Investigating the Bioequivalence of Eptacog Alfa A 6 mg and NovoSeven® in Healthy Male Subjects
Phase 1
Withdrawn
- Conditions
- Congenital Bleeding DisorderHaemophilia AHaemophilia A With InhibitorsHaemophilia BHaemophilia B With InhibitorsHealthy
- Interventions
- Drug: activated recombinant human factor VII
- First Posted Date
- 2014-03-12
- Last Posted Date
- 2014-03-26
- Lead Sponsor
- Novo Nordisk A/S
- Registration Number
- NCT02084810
Trial Investigating the Effect of Semaglutide on Energy Intake, Appetite Sensations, Postprandial Glucose and Triglyceride Metabolism and Gastric Emptying in Obese Subjects Compared With Placebo
Phase 1
Completed
- Conditions
- DiabetesObesityMetabolism and Nutrition Disorder
- Interventions
- Drug: placebo
- First Posted Date
- 2014-03-06
- Last Posted Date
- 2017-12-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 30
- Registration Number
- NCT02079870
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Leeds, United Kingdom
A Retrospective Database Assessment of Clinical Effectiveness in Type 2 Diabetes Patients Treated With Liraglutide From Primary Care Centers in Sweden
- First Posted Date
- 2014-03-04
- Last Posted Date
- 2017-05-31
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1059
- Registration Number
- NCT02077946
- Locations
- 🇸🇪
Novo Nordisk Investigational Site, Malmö, Sweden
A Trial Investigating the Influence of Oral Semaglutide on the Pharmacokinetics of Lisinopril and Warfarin in Healthy Subjects
Phase 1
Completed
- Conditions
- HealthyDiabetes
- Interventions
- First Posted Date
- 2014-02-25
- Last Posted Date
- 2020-02-17
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 52
- Registration Number
- NCT02070510
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany
A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Patients With Type 2 Diabetes in Bangladesh, Indonesia, Malaysia, Philippines, Sri Lanka and Vietnam
Completed
- Conditions
- Diabetes Mellitus, Type 2Diabetes
- Interventions
- Other: No treatment given
- First Posted Date
- 2014-02-20
- Last Posted Date
- 2019-10-23
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1631
- Registration Number
- NCT02066766
- Locations
- 🇻🇳
Novo Nordisk Investigational Site, Hanoi, Vietnam
A Thorough QTc Evaluation of the Effect of Semaglutide on Cardiac Repolarisation in Healthy Subjects
Phase 1
Completed
- Conditions
- DiabetesHealthy
- Interventions
- First Posted Date
- 2014-02-17
- Last Posted Date
- 2018-06-13
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 168
- Registration Number
- NCT02064348
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany
© Copyright 2025. All Rights Reserved by MedPath